100 + INNOVATIONS
UNSW Cellular Genomics Futures Institute( CGFI)( UNSW – Garvan Partnership)
Learn More
Genomic technology for earlier, more precise health diagnosis and treatment
Research Institute
22 affiliate labs
Challenge
Autoimmune diseases such as type 1 diabetes and rheumatoid arthritis, along with cancers including breast, colorectal and skin, impose billions in annual healthcare and productivity costs. Patients lack precise diagnostics and therapies. CGFI addresses this gap by decoding cell behaviour to enable earlier diagnosis and tailored, effective treatments.
Solution
CGFI combines AI, genomics, cell biology and clinical expertise to map immune cell behaviour at single-cell resolution. Its unique full-stack workflow, linking experimental design, sequencing, bioinformatics and translation, creates scalable datasets and tools for clinicians and industry. Anchored by the Garvan – Weizmann and Ramaciotti Centres, this capability is globally distinctive.
By focusing on autoimmune disease and cancer, CGFI accelerates translation into practice while forging sustainable partnerships with pharmaceutical companies, philanthropic organisations and government funders.
Target customers / end-users
• clinicians treating cancer and autoimmune disease
• pharmaceutical and biotech companies developing precision therapies( e. g., Novartis, Pfizer, AstraZeneca, CSL)
• government and philanthropic funders( MRFF, Cancer Council, Australian Cancer Research Foundation).
Progress
• world’ s third largest generator of single-cell genomics data
• strategic collaborations with leading pharmaceutical and biotechnology companies
• driving translation of singlecell genomics into clinical practice for cancer and autoimmune disease.
NSW Premier’ s Prize
16 major international awards
Healthy Living
CGFI integrates AI, singlecell technologies and clinical translation to advance precision medicine. As the world’ s third-largest generator of cellular genomics data, CGFI builds sustainable partnerships across industry, government and philanthropy to deliver transformative impact in cancer and autoimmune disease care worldwide.
• 105